IP Library › Granted Patent US 9,155,290
Granted Patent B2
US 9,155,290 · App. 14/514,454 · Granted Oct 13, 2015

Humanized IL-15 animals

Inventors: Jose F. Rojas (Newburgh, NY); Ka-Man Venus Lai (Tarrytown, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
A01K67/0278C07K14/5443C12N15/8509A01K2207/15A01K2217/07A01K2217/072A01K2227/105A01K2267/03A01K2267/0387C12N2015/8527
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,290
App. No.
14/514,454
Granted
Oct 13, 2015
Kind
B2
Abstract

Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.

Claims (4)

1. A genetically modified mouse whose genome comprises a replacement at an endogenous mouse IL-15 locus of a mouse genomic segment comprising sequences of mouse exons 3, 4, 5 and 6 coding for a mature mouse IL-15 polypeptide with a human genomic segment comprising human IL-15 exons coding for a mature human IL-15 polypeptide to form a humanized IL-15 gene, wherein the human IL-15 exons in said human genomic segment consist of human exons 3, 4, 5 and 6, wherein the humanized IL-15 gene is under control of endogenous mouse IL-15 upstream regulatory elements at the endogenous mouse IL-15 locus, and wherein the genetically modified mouse comprises a human IL-15 polypeptide in serum following treatment of said mouse with Poly I:C.

2. The genetically modified mouse of claim 1 , wherein the humanized IL-15-encoding gene encodes a protein which comprises the amino acid sequence of SEQ ID NO: 5.

3. A method of making a genetically modified mouse, comprising modifying the genome of a mouse by replacing at an endogenous mouse IL-15 locus of a mouse genomic segment comprising sequences of mouse exons 3, 4, 5 and 6 coding for a mature mouse IL-15 polypeptide with a human genomic segment comprising human IL-15 exons coding for a mature human IL-15 polypeptide to form a humanized IL-15 gene, wherein the human IL-15 exons in said human genomic segment consist of human exons 3, 4, 5 and 6, wherein the humanized IL-15 gene is under control of endogenous mouse IL-15 upstream regulatory elements at the endogenous mouse IL-15 locus, and wherein the genetically modified mouse comprises a human IL-15 polypeptide in serum following treatment of said genetically modified mouse with Poly I:C.

4. The method of claim 3 , wherein the humanized IL-15-encoding gene encodes a protein which comprises the amino acid sequence of SEQ ID NO: 5.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2015
From: GURER, CAGAN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 036943/0188 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2014
From: ROJAS, JOSE F.; LAI, KA-MAN VENUS; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 034290/0132 →
Continuity (2)
Provisional Application 61891013 · Oct 15, 2013
Related Publication 20150106961A1 · Apr 16, 2015